Cover Image
Market Research Report
Product code 
1088276

Clinical Trials Market Size By Phases, By Study Design, By Therapeutic Area Industry Analysis Report, Regional Outlook, Application Potential, Covid-19 Impact Analysis, Price Trends, Competitive Market Share & Forecast, 2022 - 2030

Published: | Global Market Insights Inc. | 150 Pages | Delivery time: 2-3 business days

Price

Back to Top
Clinical Trials Market Size By Phases, By Study Design, By Therapeutic Area Industry Analysis Report, Regional Outlook, Application Potential, Covid-19 Impact Analysis, Price Trends, Competitive Market Share & Forecast, 2022 - 2030
Published: June 3, 2022
Global Market Insights Inc.
Content info: 150 Pages
Delivery time: 2-3 business days
  • Description
  • Table of Contents
  • List of Tables

The clinical trials market is expected to witness substantial growth by the end of 2030 owing to a growing trend of outsourcing clinical trials to CROs. In addition, increasing research and development due to rising incidences of chronic diseases are likely to further boost market growth over the forecast period.

During the COVID-19 pandemic, restrictions on movement and various discrepancies in the healthcare sector posed a threat to market growth. Many clinical trial projects were either halted or postponed in light of the implications of COVID-19. However, ease in lockdown restrictions and declining cases across key regions have been favorable for the business scenario. Government funding and grants for clinical trials have also pushed healthcare companies to outsource clinical trials to CROs.

Additionally, major players in the industry have been focusing on new service launches and growth strategies like collaborations and partnerships to improve their standing in the competitive landscape. For instance, in February 2021, LabCorp, also known as Laboratory Corporation of America Holdings, a life sciences company, collaborated with Circuit Clinical, an American integrated research organization, to bring clinical trials to provide direct access to underrepresented patients. The collaboration was intended to give a broad and diverse patient population, who are otherwise neglected, the opportunity to participate in clinical trials.

To cite another instance, in April 2021, Bioclinica, a clinical trial service provider, introduced its new source document management solution integrated with advanced software and redaction & translation services to back global research site and trial management.

In another instance, in February 2021, ICON, a global clinical research organization, acquired PRA Health Sciences, a key participant in the market, for approximately $12 billion. The deal brought together the two firms that have a shared focus on high-quality and efficient clinical trial execution.

The clinical trials market has been segmented in terms of therapeutic area, phase, study design, and region. On the basis of phase, the clinical trials market has been divided into phase I, phase II, phase III, and phase IV. The phase I segment accounted for above $8,450.1 million in revenue in 2021.

With respect to study design, the industry has been bifurcated into expanded access study, interventional study, and observational study. The observational study segment held around 20.7% market share in 2021.

In terms of therapeutic area, the clinical trials industry has been categorized into oncology, infectious disease, autoimmune disease, ophthalmology, cardiology, dermatology, and others. The ophthalmology segment is expected to be valued at approximately $5,319.9 million by the end of 2030.

In the regional landscape, Latin America accounted for over 3.9% of the overall industry revenue in 2021. Meanwhile, the clinical trials market in Middle East & Africa is anticipated to grow at a steady rate of more than 6.6% through the analysis period.

Product Code: 5029

Table of Contents

Chapter 1 Methodology

  • 1.1 Market definitions
  • 1.2 Base estimates & working
    • 1.2.1 North America
    • 1.2.2 Europe
    • 1.2.3 Asia Pacific
    • 1.2.4 Latin America
    • 1.2.5 Middle East & Africa
  • 1.3 Forecast parameters
  • 1.4 Data validation
  • 1.5 Data Sources
    • 1.5.1 Secondary
      • 1.5.1.1 Paid sources
      • 1.5.1.2 Unpaid sources
    • 1.5.2 Primary

Chapter 2 Executive Summary

  • 2.1 Clinical trials industry 360 degree synopsis, 2017-2030
    • 2.1.1 Business trends
    • 2.1.2 Phase trends
    • 2.1.3 Study design trends
    • 2.1.4 Therapeutic area trends
    • 2.1.5 Regional trends

Chapter 3 Clinical trials Industry Insights

  • 3.1 Industry segmentation
  • 3.2 Industry landscape, 2017-2030 (USD Million)
  • 3.3 Industry impact forces
    • 3.3.1 Growth drivers
      • 3.3.1.1 Increasing prevalence of chronic diseases across the globe
      • 3.3.1.2 Growing demand for outsourcing clinical trials to CROs
      • 3.3.1.3 Rise in government and non-government funding for clinical trials
      • 3.3.1.4 Growing opportunities for conducting clinical trials in countries of Asia Pacific
    • 3.3.2 Industry pitfalls & challenges
      • 3.3.2.1 Lack of skilled workforce in clinical research
      • 3.3.2.2 Infrastructural barriers in developing countries
      • 3.3.2.3 Challenges faced in North America & Europe for conducting clinical trials
  • 3.4 Growth potential analysis
    • 3.4.1 By phase
    • 3.4.2 By study design
    • 3.4.3 By therapeutic areas
  • 3.5 COVID-19 impact analysis
  • 3.6 Clinical trial volume analysis
    • 3.6.1 Clinical trial volume analysis, by region, 2017-2020
    • 3.6.2 Clinical trial volume analysis, by indication, 2017-2020
    • 3.6.3 Clinical trial volume analysis, by phase of development, 2017-2020
  • 3.7 Regulatory landscape
    • 3.7.1 U.S.
    • 3.7.2 Europe
    • 3.7.3 Asia Pacific
      • 3.7.3.1 Singapore
      • 3.7.3.2 Malaysia
      • 3.7.3.3 Indonesia
      • 3.7.3.4 Thailand
      • 3.7.3.5 South Korea
      • 3.7.3.6 Philippines
  • 3.8 Clinical trials- Asia Pacific advantage
  • 3.9 Competitive landscape, 2021
    • 3.9.1 Company matrix analysis
  • 3.10 Porter's analysis
  • 3.11 PESTEL analysis

Chapter 4 Clinical Trials Market, By Phase

  • 4.1 Key segment trends
  • 4.2 Phase I
    • 4.2.1 Market size, by region, 2017-2030 (USD Million)
  • 4.3 Phase II
    • 4.3.1 Market size, by region, 2017-2030 (USD Million)
  • 4.4 Phase III
    • 4.4.1 Market size, by region, 2017-2030 (USD Million)
  • 4.5 Phase IV
    • 4.5.1 Market size, by region, 2017-2030 (USD Million)

Chapter 5 Clinical Trials Market, By Study Design

  • 5.1 Key segment trend
  • 5.2 Interventional study
    • 5.2.1 Market size, by region, 2017-2030 (USD Million)
  • 5.3 Observational study
    • 5.3.1 Market size, by region, 2017-2030 (USD Million)
  • 5.4 Expanded access study
    • 5.4.1 Market size, by region, 2017-2030 (USD Million)

Chapter 6 Clinical Trials Market, By Therapeutic Area

  • 6.1 Key segment trend
  • 6.2 Autoimmune disease
    • 6.2.1 Market size, by region, 2017-2030 (USD Million)
  • 6.3 Oncology
    • 6.3.1 Market size, by region, 2017-2030 (USD Million)
  • 6.4 Cardiology
    • 6.4.1 Market size, by region, 2017-2030 (USD Million)
  • 6.5 Infectious disease
    • 6.5.1 Market size, by region, 2017-2030 (USD Million)
  • 6.6 Dermatology
    • 6.6.1 Market size, by region, 2017-2030 (USD Million)
  • 6.7 Ophthalmology
    • 6.7.1 Market size, by region, 2017-2030 (USD Million)
  • 6.8 Others
    • 6.8.1 Market size, by region, 2017-2030 (USD Million)

Chapter 7 Clinical Trials Market, By Region

  • 7.1 Key regional trends
  • 7.2 North America
    • 7.2.1 Market size, by country, 2017-2030 (USD Million)
    • 7.2.2 Market size, by phase, 2017-2030 (USD Million)
    • 7.2.3 Market size, by study design, 2017-2030 (USD Million)
    • 7.2.4 Market size, by therapeutic area, 2017-2030 (USD Million)
    • 7.2.5 U.S.
      • 7.2.5.1 Market size, by phase, 2017-2030 (USD Million)
      • 7.2.5.2 Market size, by study design, 2017-2030 (USD Million)
      • 7.2.5.3 Market size, by therapeutic area, 2017-2030 (USD Million)
    • 7.2.6 Canada
      • 7.2.6.1 Market size, by phase, 2017-2030 (USD Million)
      • 7.2.6.2 Market size, by study design, 2017-2030 (USD Million)
      • 7.2.6.3 Market size, by therapeutic area, 2017-2030 (USD Million)
  • 7.3 Europe
    • 7.3.1 Market size, by country, 2017-2030 (USD Million)
    • 7.3.2 Market size, by phase, 2017-2030 (USD Million)
    • 7.3.3 Market size, by study design, 2017-2030 (USD Million)
    • 7.3.4 Market size, by therapeutic area, 2017-2030 (USD Million)
    • 7.3.5 Germany
      • 7.3.5.1 Market size, by phase, 2017-2030 (USD Million)
      • 7.3.5.2 Market size, by study design, 2017-2030 (USD Million)
      • 7.3.5.3 Market size, by therapeutic area, 2017-2030 (USD Million)
    • 7.3.6 UK
      • 7.3.6.1 Market size, by phase, 2017-2030 (USD Million)
      • 7.3.6.2 Market size, by study design, 2017-2030 (USD Million)
      • 7.3.6.3 Market size, by therapeutic area, 2017-2030 (USD Million)
    • 7.3.7 France
      • 7.3.7.1 Market size, by phase, 2017-2030 (USD Million)
      • 7.3.7.2 Market size, by study design, 2017-2030 (USD Million)
      • 7.3.7.3 Market size, by therapeutic area, 2017-2030 (USD Million)
    • 7.3.8 Spain
      • 7.3.8.1 Market size, by phase, 2017-2030 (USD Million)
      • 7.3.8.2 Market size, by study design, 2017-2030 (USD Million)
      • 7.3.8.3 Market size, by therapeutic area, 2017-2030 (USD Million)
    • 7.3.9 Italy
      • 7.3.9.1 Market size, by phase, 2017-2030 (USD Million)
      • 7.3.9.2 Market size, by study design, 2017-2030 (USD Million)
      • 7.3.9.3 Market size, by therapeutic area, 2017-2030 (USD Million)
  • 7.4 Asia Pacific
    • 7.4.1 Market size, by country, 2017-2030 (USD Million)
    • 7.4.2 Market size, by phase, 2017-2030 (USD Million)
    • 7.4.3 Market size, by study design, 2017-2030 (USD Million)
    • 7.4.4 Market size, by therapeutic area, 2017-2030 (USD Million)
    • 7.4.5 China
      • 7.4.5.1 Market size, by phase, 2017-2030 (USD Million)
      • 7.4.5.2 Market size, by study design, 2017-2030 (USD Million)
      • 7.4.5.3 Market size, by therapeutic area, 2017-2030 (USD Million)
    • 7.4.6 Japan
      • 7.4.6.1 Market size, by phase, 2017-2030 (USD Million)
      • 7.4.6.2 Market size, by study design, 2017-2030 (USD Million)
      • 7.4.6.3 Market size, by therapeutic area, 2017-2030 (USD Million)
    • 7.4.7 India
      • 7.4.7.1 Market size, by phase, 2017-2030 (USD Million)
      • 7.4.7.2 Market size, by study design, 2017-2030 (USD Million)
      • 7.4.7.3 Market size, by therapeutic area, 2017-2030 (USD Million)
    • 7.4.8 Australia
      • 7.4.8.1 Market size, by phase, 2017-2030 (USD Million)
      • 7.4.8.2 Market size, by study design, 2017-2030 (USD Million)
      • 7.4.8.3 Market size, by therapeutic area, 2017-2030 (USD Million)
    • 7.4.9 South Korea
      • 7.4.9.1 Market size, by phase, 2017-2030 (USD Million)
      • 7.4.9.2 Market size, by study design, 2017-2030 (USD Million)
      • 7.4.9.3 Market size, by therapeutic area, 2017-2030 (USD Million)
    • 7.4.10 Singapore
      • 7.4.10.1 Market size, by phase, 2017-2030 (USD Million)
      • 7.4.10.2 Market size, by study design, 2017-2030 (USD Million)
      • 7.4.10.3 Market size, by therapeutic area, 2017-2030 (USD Million)
    • 7.4.11 Malaysia
      • 7.4.11.1 Market size, by phase, 2017-2030 (USD Million)
      • 7.4.11.2 Market size, by study design, 2017-2030 (USD Million)
      • 7.4.11.3 Market size, by therapeutic area, 2017-2030 (USD Million)
    • 7.4.12 Indonesia
      • 7.4.12.1 Market size, by phase, 2017-2030 (USD Million)
      • 7.4.12.2 Market size, by study design, 2017-2030 (USD Million)
      • 7.4.12.3 Market size, by therapeutic area, 2017-2030 (USD Million)
    • 7.4.13 Thailand
      • 7.4.13.1 Market size, by phase, 2017-2030 (USD Million)
      • 7.4.13.2 Market size, by study design, 2017-2030 (USD Million)
      • 7.4.13.3 Market size, by therapeutic area, 2017-2030 (USD Million)
    • 7.4.14 Philippines
      • 7.4.14.1 Market size, by phase, 2017-2030 (USD Million)
      • 7.4.14.2 Market size, by study design, 2017-2030 (USD Million)
      • 7.4.14.3 Market size, by therapeutic area, 2017-2030 (USD Million)
  • 7.5 Latin America
    • 7.5.1 Market size, by country, 2017-2030 (USD Million)
    • 7.5.2 Market size, by phase, 2017-2030 (USD Million)
    • 7.5.3 Market size, by study design, 2017-2030 (USD Million)
    • 7.5.4 Market size, by therapeutic area, 2017-2030 (USD Million)
    • 7.5.5 Brazil
      • 7.5.5.1 Market size, by phase, 2017-2030 (USD Million)
      • 7.5.5.2 Market size, by study design, 2017-2030 (USD Million)
      • 7.5.5.3 Market size, by therapeutic area, 2017-2030 (USD Million)
    • 7.5.6 Mexico
      • 7.5.6.1 Market size, by phase, 2017-2030 (USD Million)
      • 7.5.6.2 Market size, by study design, 2017-2030 (USD Million)
      • 7.5.6.3 Market size, by therapeutic area, 2017-2030 (USD Million)
  • 7.6 Middle East and Africa
    • 7.6.1 Market size, by country, 2017-2030 (USD Million)
    • 7.6.2 Market size, by phase, 2017-2030 (USD Million)
    • 7.6.3 Market size, by study design, 2017-2030 (USD Million)
    • 7.6.4 Market size, by therapeutic area, 2017-2030 (USD Million)
    • 7.6.5 South Africa
      • 7.6.5.1 Market size, by phase, 2017-2030 (USD Million)
      • 7.6.5.2 Market size, by study design, 2017-2030 (USD Million)
      • 7.6.5.3 Market size, by therapeutic area, 2017-2030 (USD Million)
    • 7.6.6 Saudi Arabia
      • 7.6.6.1 Market size, by phase, 2017-2030 (USD Million)
      • 7.6.6.2 Market size, by study design, 2017-2030 (USD Million)
      • 7.6.6.3 Market size, by therapeutic area, 2017-2030 (USD Million)

Chapter 8 Company Profiles

  • 8.1 Competitive dashboard, 2021
  • 8.2 Clario
    • 8.2.1 Business overview
    • 8.2.2 Financial data
    • 8.2.3 Product landscape
    • 8.2.4 Strategic outlook
    • 8.2.5 SWOT analysis
  • 8.3 Charles River Laboratories (MPI Research)
    • 8.3.1 Business overview
    • 8.3.2 Financial data
    • 8.3.3 Product landscape
    • 8.3.4 Strategic outlook
    • 8.3.5 SWOT analysis
  • 8.4 Clinipace Inc
    • 8.4.1 Business overview
    • 8.4.2 Financial data
    • 8.4.3 Product landscape
    • 8.4.4 Strategic outlook
    • 8.4.5 SWOT analysis
  • 8.5 ICON plc
    • 8.5.1 Business overview
    • 8.5.2 Financial data
    • 8.5.3 Product landscape
    • 8.5.4 Strategic outlook
    • 8.5.5 SWOT analysis
  • 8.6 IQVIA
    • 8.6.1 Business overview
    • 8.6.2 Financial data
    • 8.6.3 Product landscape
    • 8.6.4 Strategic outlook
    • 8.6.5 SWOT analysis
  • 8.7 Laboratory Corporation of America Holding (Covance Inc)
    • 8.7.1 Business overview
    • 8.7.2 Financial data
    • 8.7.3 Product landscape
    • 8.7.4 Strategic outlook
    • 8.7.5 SWOT analysis
  • 8.8 Medpace
    • 8.8.1 Business overview
    • 8.8.2 Financial data
    • 8.8.3 Product landscape
    • 8.8.4 Strategic outlook
    • 8.8.5 SWOT analysis
  • 8.9 Parexel International Corporation
    • 8.9.1 Business overview
    • 8.9.2 Financial data
    • 8.9.3 Product landscape
    • 8.9.4 Strategic outlook
    • 8.9.5 SWOT analysis
  • 8.10 Pharmaceutical Product Development, LLC (PPD)
    • 8.10.1 Business overview
    • 8.10.2 Financial data
    • 8.10.3 Product landscape
    • 8.10.4 Strategic outlook
    • 8.10.5 SWOT analysis
  • 8.11 Syneos health
    • 8.11.1 Business overview
    • 8.11.2 Financial data
    • 8.11.3 Product landscape
    • 8.11.4 Strategic outlook
    • 8.11.5 SWOT analysis
  • 8.12 The Emmes Company, LLC
    • 8.12.1 Business overview
    • 8.12.2 Financial data
    • 8.12.3 Product landscape
    • 8.12.4 Strategic outlook
    • 8.12.5 SWOT analysis
  • 8.13 WuXi AppTec
    • 8.13.1 Business overview
    • 8.13.2 Financial data
    • 8.13.3 Product landscape
    • 8.13.4 Strategic outlook
    • 8.13.5 SWOT analysis

Data Tables

  • TABLE 1 Global clinical trials market, 2017-2021 (USD Million)
  • TABLE 2 Global clinical trials market, 2022-2030 (USD Million)
  • TABLE 3 Global clinical trials market, by phase, 2017-2021 (USD Million)
  • TABLE 4 Global clinical trials market, by phase, 2022-2030 (USD Million)
  • TABLE 5 Global clinical trials market, by study design, 2017-2021 (USD Million)
  • TABLE 6 Global clinical trials market, by study design, 2022-2030 (USD Million)
  • TABLE 7 Global clinical trials market, by therapeutic area, 2017-2021 (USD Million)
  • TABLE 8 Global clinical trials market, by therapeutic area, 2022-2030 (USD Million)
  • TABLE 9 Global clinical trials market, by region, 2017-2021 (USD Million)
  • TABLE 10 Global clinical trials market, by region, 2022-2030 (USD Million)
  • TABLE 11 Industry impact forces
  • TABLE 12 Clinical trial volume analysis, by region, 2017-2020
  • TABLE 13 Clinical trial volume analysis, by indication, 2017-2020
  • TABLE 14 Clinical trial volume analysis, by phase of development, 2017-2020
  • TABLE 15 Phase I market size, by region, 2017-2021(USD Million)
  • TABLE 16 Phase I market size, by region, 2022-2030 (USD Million)
  • TABLE 17 Phase II market size, by region, 2017-2021 (USD Million)
  • TABLE 18 Phase II market size, by region, 2022-2030 (USD Million)
  • TABLE 19 Phase III market size, by region, 2017-2021 (USD Million)
  • TABLE 20 Phase III market size, by region, 2022-2030 (USD Million)
  • TABLE 21 Phase IV market size, by region, 2017-2021 (USD Million)
  • TABLE 22 Phase IV market size, by region, 2022-2030 (USD Million)
  • TABLE 23 Interventional study market size, by region, 2017-2021 (USD Million)
  • TABLE 24 Interventional study market size, by region, 2022-2030 (USD Million)
  • TABLE 25 Observational study market size, by region, 2017-2021 (USD Million)
  • TABLE 26 Observational study market size, by region, 2022-2030 (USD Million)
  • TABLE 27 Expanded access study market size, by region, 2017-2021 (USD Million)
  • TABLE 28 Expanded access study market size, by region, 2022-2030 (USD Million)
  • TABLE 29 Autoimmune disease market size, by region, 2017-2021 (USD Million)
  • TABLE 30 Autoimmune disease market size, by region, 2022-2030 (USD Million)
  • TABLE 31 Oncology market size, by region, 2017-2021 (USD Million)
  • TABLE 32 Oncology market size, by region, 2022-2030 (USD Million)
  • TABLE 33 Cardiology market size, by region, 2017-2021 (USD Million)
  • TABLE 34 Cardiology market size, by region, 2022-2030 (USD Million)
  • TABLE 35 Infectious disease market size, by region, 2017-2021 (USD Million)
  • TABLE 36 Infectious disease market size, by region, 2022-2030 (USD Million)
  • TABLE 37 Dermatology market size, by region, 2017-2021 (USD Million)
  • TABLE 38 Dermatology market size, by region, 2021 - 20207 (USD Million)
  • TABLE 39 Ophthalmology market size, by region, 2017-2021 (USD Million)
  • TABLE 40 Ophthalmology market size, by region, 2022-2030 (USD Million)
  • TABLE 41 Others market size, by region, 2017-2021 (USD Million)
  • TABLE 42 Others market size, by region, 2022-2030 (USD Million)
  • TABLE 43 North America clinical trials market size, by country, 2017-2021 (USD Million)
  • TABLE 44 North America clinical trials market size, by country, 2022-2030 (USD Million)
  • TABLE 45 North America clinical trials market size, by phase, 2017-2021 (USD Mn)
  • TABLE 46 North America clinical trials market size, by phase, 2022-2030 (USD Mn)
  • TABLE 47 North America clinical trials market size, by study design, 2017-2021 (USD Million)
  • TABLE 48 North America clinical trials market size, by study design, 2022-2030 (USD Million)
  • TABLE 49 North America clinical trials market size, by therapeutic area, 2017-2021 (USD Million)
  • TABLE 50 North America clinical trials market size, by therapeutic area, 2022-2030 (USD Million)
  • TABLE 51 U.S. clinical trials market size, by phase, 2017-2021 (USD Million)
  • TABLE 52 U.S. clinical trials market size, by phase, 2022-2030 (USD Million)
  • TABLE 53 U.S. clinical trials market size, by study design, 2017-2021 (USD Million)
  • TABLE 54 U.S. clinical trials market size, by study design, 2022-2030 (USD Million)
  • TABLE 55 U.S. clinical trials market size, by therapeutic area, 2017-2021 (USD Million)
  • TABLE 56 U.S. clinical trials market size, by therapeutic area, 2022-2030 (USD Million)
  • TABLE 57 Canada clinical trials market size, by phase, 2017-2021 (USD Million)
  • TABLE 58 Canada clinical trials market size, by phase, 2022-2030 (USD Million)
  • TABLE 59 Canada clinical trials market size, by study design, 2017-2021 (USD Million)
  • TABLE 60 Canada clinical trials market size, by study design, 2022-2030 (USD Million)
  • TABLE 61 Canada clinical trials market size, by therapeutic area, 2017-2021 (USD Million)
  • TABLE 62 Canada clinical trials market size, by therapeutic area, 2022-2030 (USD Million)
  • TABLE 63 Europe clinical trials market size, by country, 2017-2021 (USD Million)
  • TABLE 64 Europe clinical trials market size, by country, 2022-2030 (USD Million)
  • TABLE 65 Europe clinical trials market size, by phase, 2017-2021 (USD Million)
  • TABLE 66 Europe clinical trials market size, by phase, 2022-2030 (USD Million)
  • TABLE 67 Europe clinical trials market size, by study design, 2017-2021 (USD Million)
  • TABLE 68 Europe clinical trials market size, by study design, 2022-2030 (USD Million)
  • TABLE 69 Europe clinical trials market size, by therapeutic area, 2017-2021 (USD Million)
  • TABLE 70 Europe clinical trials market size, by therapeutic area, 2022-2030 (USD Million)
  • TABLE 71 Germany clinical trials market size, by phase, 2017-2021 (USD Million)
  • TABLE 72 Germany clinical trials market size, by phase, 2022-2030 (USD Million)
  • TABLE 73 Germany clinical trials market size, by study design, 2017-2021 (USD Million)
  • TABLE 74 Germany clinical trials market size, by study design, 2022-2030 (USD Million)
  • TABLE 75 Germany clinical trials market size, by therapeutic area, 2017-2021 (USD Million)
  • TABLE 76 Germany clinical trials market size, by therapeutic area, 2022-2030 (USD Million)
  • TABLE 77 UK clinical trials market size, by phase, 2017-2021 (USD Million)
  • TABLE 78 UK clinical trials market size, by phase, 2022-2030 (USD Million)
  • TABLE 79 UK clinical trials market size, by study design, 2017-2021 (USD Million)
  • TABLE 80 UK clinical trials market size, by study design, 2022-2030 (USD Million)
  • TABLE 81 UK clinical trials market size, by therapeutic area, 2017-2021 (USD Million)
  • TABLE 82 UK clinical trials market size, by therapeutic area, 2022-2030 (USD Million)
  • TABLE 83 France clinical trials market size, by phase, 2017-2021 (USD Million)
  • TABLE 84 France clinical trials market size, by phase, 2022-2030 (USD Million)
  • TABLE 85 France clinical trials market size, by study design, 2017-2021 (USD Million)
  • TABLE 86 France clinical trials market size, by study design, 2022-2030 (USD Million)
  • TABLE 87 France clinical trials market size, by therapeutic area, 2017-2021 (USD Million)
  • TABLE 88 France clinical trials market size, by therapeutic area, 2022-2030 (USD Million)
  • TABLE 89 Spain clinical trials market size, by phase, 2017-2021 (USD Million)
  • TABLE 90 Spain clinical trials market size, by phase, 2022-2030 (USD Million)
  • TABLE 91 Spain clinical trials market size, by study design, 2017-2021 (USD Million)
  • TABLE 92 Spain clinical trials market size, by study design, 2022-2030 (USD Million)
  • TABLE 93 Spain clinical trials market size, by therapeutic area, 2017-2021 (USD Million)
  • TABLE 94 Spain clinical trials market size, by therapeutic area, 2022-2030 (USD Million)
  • TABLE 95 Italy clinical trials market size, by phase, 2017-2021 (USD Million)
  • TABLE 96 Italy clinical trials market size, by phase, 2022-2030 (USD Million)
  • TABLE 97 Italy clinical trials market size, by study design, 2017-2021 (USD Million)
  • TABLE 98 Italy clinical trials market size, by study design, 2022-2030 (USD Million)
  • TABLE 99 Italy clinical trials market size, by therapeutic area, 2017-2021 (USD Million)
  • TABLE 100 Italy clinical trials market size, by therapeutic area, 2022-2030 (USD Million)
  • TABLE 101 Asia Pacific clinical trials market size, by country, 2017-2021 (USD Million)
  • TABLE 102 Asia Pacific clinical trials market size, by country, 2022-2030 (USD Million)
  • TABLE 103 Asia Pacific clinical trials market size, by phase, 2017-2021 (USD Million)
  • TABLE 104 Asia Pacific clinical trials market size, by phase, 2022-2030 (USD Million)
  • TABLE 105 Asia Pacific clinical trials market size, by study design, 2017-2021 (USD Million)
  • TABLE 106 Asia Pacific clinical trials market size, by study design, 2022-2030 (USD Million)
  • TABLE 107 Asia Pacific clinical trials market size, by therapeutic area, 2017-2021 (USD Million)
  • TABLE 108 Asia Pacific clinical trials market size, by therapeutic area, 2022-2030 (USD Million)
  • TABLE 109 China clinical trials market size, by phase, 2017-2021 (USD Million)
  • TABLE 110 China clinical trials market size, by phase, 2022-2030 (USD Million)
  • TABLE 111 China clinical trials market size, by study design, 2017-2021 (USD Million)
  • TABLE 112 China clinical trials market size, by study design, 2022-2030 (USD Million)
  • TABLE 113 China clinical trials market size, by therapeutic area, 2017-2021 (USD Million)
  • TABLE 114 China clinical trials market size, by therapeutic area, 2022-2030 (USD Million)
  • TABLE 115 Japan clinical trials market size, by phase, 2017-2021 (USD Million)
  • TABLE 116 Japan clinical trials market size, by phase, 2022-2030 (USD Million)
  • TABLE 117 Japan clinical trials market size, by study design, 2017-2021 (USD Million)
  • TABLE 118 Japan clinical trials market size, by study design, 2022-2030 (USD Million)
  • TABLE 119 Japan clinical trials market size, by therapeutic area, 2017-2021 (USD Million)
  • TABLE 120 Japan clinical trials market size, by therapeutic area, 2022-2030 (USD Million)
  • TABLE 121 India clinical trials market size, by phase, 2017-2021 (USD Million)
  • TABLE 122 India clinical trials market size, by phase, 2022-2030 (USD Million)
  • TABLE 123 India clinical trials market size, by study design, 2017-2021 (USD Million)
  • TABLE 124 India clinical trials market size, by study design, 2022-2030 (USD Million)
  • TABLE 125 India clinical trials market size, by therapeutic area, 2017-2021 (USD Million)
  • TABLE 126 India clinical trials market size, by therapeutic area, 2022-2030 (USD Million)
  • TABLE 127 Australia clinical trials market size, by phase, 2017-2021 (USD Million)
  • TABLE 128 Australia clinical trials market size, by phase, 2022-2030 (USD Million)
  • TABLE 129 Australia clinical trials market size, by study design, 2017-2021 (USD Million)
  • TABLE 130 Australia clinical trials market size, by study design, 2022-2030 (USD Million)
  • TABLE 131 Australia clinical trials market size, by therapeutic area, 2017-2021 (USD Million)
  • TABLE 132 Australia clinical trials market size, by therapeutic area, 2022-2030 (USD Million)
  • TABLE 133 South Korea clinical trials market size, by phase, 2017-2021 (USD Million)
  • TABLE 134 South Korea clinical trials market size, by phase, 2022-2030 (USD Million)
  • TABLE 135 South Korea clinical trials market size, by study design, 2017-2021 (USD Million)
  • TABLE 136 South Korea clinical trials market size, by study design, 2022-2030 (USD Million)
  • TABLE 137 South Korea clinical trials market size, by therapeutic area, 2017-2021 (USD Million)
  • TABLE 138 South Korea clinical trials market size, by therapeutic area, 2022-2030 (USD Million)
  • TABLE 139 Singapore clinical trials market size, by phase, 2017-2021 (USD Million)
  • TABLE 140 Singapore clinical trials market size, by phase, 2022-2030 (USD Million)
  • TABLE 141 Singapore clinical trials market size, by study design, 2017-2021 (USD Million)
  • TABLE 142 Singapore clinical trials market size, by study design, 2022-2030 (USD Million)
  • TABLE 143 Singapore clinical trials market size, by therapeutic area, 2017-2021 (USD Million)
  • TABLE 144 Singapore clinical trials market size, by therapeutic area, 2022-2030 (USD Million)
  • TABLE 145 Malaysia clinical trials market size, by phase, 2017-2021 (USD Million)
  • TABLE 146 Malaysia clinical trials market size, by phase, 2022-2030 (USD Million)
  • TABLE 147 Malaysia clinical trials market size, by study design, 2017-2021 (USD Million)
  • TABLE 148 Malaysia clinical trials market size, by study design, 2022-2030 (USD Million)
  • TABLE 149 Malaysia clinical trials market size, by therapeutic area, 2017-2021 (USD Million)
  • TABLE 150 Malaysia clinical trials market size, by therapeutic area, 2022-2030 (USD Million)
  • TABLE 151 Indonesia clinical trials market size, by phase, 2017-2021 (USD Million)
  • TABLE 152 Indonesia clinical trials market size, by phase, 2022-2030 (USD Million)
  • TABLE 153 Indonesia clinical trials market size, by study design, 2017-2021 (USD Million)
  • TABLE 154 Indonesia clinical trials market size, by study design, 2022-2030 (USD Million)
  • TABLE 155 Indonesia clinical trials market size, by therapeutic area, 2017-2021 (USD Million)
  • TABLE 156 Indonesia clinical trials market size, by therapeutic area, 2022-2030 (USD Million)
  • TABLE 157 Thailand clinical trials market size, by phase, 2017-2021 (USD Million)
  • TABLE 158 Thailand clinical trials market size, by phase, 2022-2030 (USD Million)
  • TABLE 159 Thailand clinical trials market size, by study design, 2017-2021 (USD Million)
  • TABLE 160 Thailand clinical trials market size, by study design, 2022-2030 (USD Million)
  • TABLE 161 Thailand clinical trials market size, by therapeutic area, 2017-2021 (USD Million)
  • TABLE 162 Thailand clinical trials market size, by therapeutic area, 2022-2030 (USD Million)
  • TABLE 163 Philippines clinical trials market size, by phase, 2017-2021 (USD Million)
  • TABLE 164 Philippines clinical trials market size, by phase, 2022-2030 (USD Million)
  • TABLE 165 Philippines clinical trials market size, by study design, 2017-2021 (USD Million)
  • TABLE 166 Philippines clinical trials market size, by study design, 2022-2030 (USD Million)
  • TABLE 167 Philippines clinical trials market size, by therapeutic area, 2017-2021 (USD Million)
  • TABLE 168 Philippines clinical trials market size, by therapeutic area, 2022-2030 (USD Million)
  • TABLE 169 Latin America clinical trials market size, by country, 2017-2021 (USD Million)
  • TABLE 170 Latin America clinical trials market size, by country, 2022-2030 (USD Million)
  • TABLE 171 Latin America clinical trials market size, by phase, 2017-2021 (USD Million)
  • TABLE 172 Latin America clinical trials market size, by phase, 2022-2030 (USD Million)
  • TABLE 173 Latin America clinical trials market size, by study design, 2017-2021 (USD Million)
  • TABLE 174 Latin America clinical trials market size, by study design, 2022-2030 (USD Million)
  • TABLE 175 Latin America clinical trials market size, by therapeutic area, 2017-2021 (USD Million)
  • TABLE 176 Latin America clinical trials market size, by therapeutic area, 2022-2030 (USD Million)
  • TABLE 177 Brazil clinical trials market size, by phase, 2017-2021 (USD Million)
  • TABLE 178 Brazil clinical trials market size, by phase, 2022-2030 (USD Million)
  • TABLE 179 Brazil clinical trials market size, by study design, 2017-2021 (USD Million)
  • TABLE 180 Brazil clinical trials market size, by study design, 2022-2030 (USD Million)
  • TABLE 181 Brazil clinical trials market size, by therapeutic area, 2017-2021 (USD Million)
  • TABLE 182 Brazil clinical trials market size, by therapeutic area, 2022-2030 (USD Million)
  • TABLE 183 Mexico clinical trials market size, by phase, 2017-2021 (USD Million)
  • TABLE 184 Mexico clinical trials market size, by phase, 2022-2030 (USD Million)
  • TABLE 185 Mexico clinical trials market size, by study design, 2017-2021 (USD Million)
  • TABLE 186 Mexico clinical trials market size, by study design, 2022-2030 (USD Million)
  • TABLE 187 Mexico clinical trials market size, by therapeutic area, 2017-2021 (USD Million)
  • TABLE 188 Mexico clinical trials market size, by therapeutic area, 2022-2030 (USD Million)
  • TABLE 189 Middle East & Africa clinical trials market size, by country, 2017-2021 (USD Million)
  • TABLE 190 Middle East & Africa clinical trials market size, by country, 2022-2030 (USD Million)
  • TABLE 191 Middle East & Africa clinical trials market size, by phase, 2017-2021 (USD Million)
  • TABLE 192 Middle East & Africa clinical trials market size, by phase, 2022-2030 (USD Million)
  • TABLE 193 Middle East & Africa clinical trials market size, by study design, 2017-2021 (USD Million)
  • TABLE 194 Middle East & Africa clinical trials market size, by study design, 2022-2030 (USD Million)
  • TABLE 195 Middle East & Africa clinical trials market size, by therapeutic area, 2017-2021 (USD Million)
  • TABLE 196 Middle East & Africa clinical trials market size, by therapeutic area, 2022-2030 (USD Million)
  • TABLE 197 South Africa clinical trials market size, by phase, 2017-2021 (USD Million)
  • TABLE 198 South Africa clinical trials market size, by phase, 2022-2030 (USD Million)
  • TABLE 199 South Africa clinical trials market size, by study design, 2017-2021 (USD Million)
  • TABLE 200 South Africa clinical trials market size, by study design, 2022-2030 (USD Million)
  • TABLE 201 South Africa clinical trials market size, by therapeutic area, 2017-2021 (USD Million)
  • TABLE 202 South Africa clinical trials market size, by therapeutic area, 2022-2030 (USD Million)
  • TABLE 203 Saudi Arabia clinical trials market size, by phase, 2017-2021 (USD Million)
  • TABLE 204 Saudi Arabia clinical trials market size, by phase, 2022-2030 (USD Million)
  • TABLE 205 Saudi Arabia clinical trials market size, by study design, 2017-2021 (USD Million)
  • TABLE 206 Saudi Arabia clinical trials market size, by study design, 2022-2030 (USD Million)
  • TABLE 207 Saudi Arabia clinical trials market size, by therapeutic area, 2017-2021 (USD Million)
  • TABLE 208 Saudi Arabia clinical trials market size, by therapeutic area, 2022-2030 (USD Million)

Charts & Figures

  • FIG. 1 Top-down approach
  • FIG. 2 Breakdown of primary participants
  • FIG. 3 Clinical trials industry 360 degree synopsis, 2017-2030
  • FIG. 4 Industry segmentation
  • FIG. 5 Industry landscape, 2017-2030 (USD Million)
  • FIG. 6 Growth potential analysis, by phase
  • FIG. 7 Growth potential analysis, by study design
  • FIG. 8 Growth potential analysis, by therapeutic area
  • FIG. 9 Company matrix analysis, 2021
  • FIG. 10 Porter's analysis
  • FIG. 11 PESTEL analysis
  • FIG. 12 Key segment trends, by phase
  • FIG. 13 Key segment trends, by study design
  • FIG. 14 Key segment trends, by therapeutic area
  • FIG. 15 Key regional trends
  • FIG. 16 Competitive dashboard, 2021